What Optigo Biotherapeutics does

Optigo Biotherapeutics Inc. is a preclinical-stage biotherapeutics company headquartered in Vancouver, British Columbia, that develops sustained-release treatments for blinding retinal diseases including neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), geographic atrophy (GA), and retinal vein occlusion. Founded in 2018, the company is small (1-10 employees) and privately held, focused exclusively on reducing the burden of frequent intravitreal injections that currently define the standard of care for these conditions.

The company's core technology is the Vitreous Anchor Platform, a proprietary set of precision-targeted protein domains that bind to hyaluronic acid and albumin within the vitreous gel. These domains can be fused to existing and future retinal biologics to create bi-specific molecules that anchor the therapeutic to the vitreous, extending half-life and duration of action without compromising efficacy. The lead asset is a long-acting anti-VEGF therapy engineered by fusing the anchor domain to a derisked anti-angiogenic backbone (positioned around aflibercept-class biology), designed for once-yearly intravitreal dosing compared to the current monthly or bimonthly standard. Preclinical data presented at ARVO 2025 and Eyecelerator 2025 demonstrated 2-3x longer half-life versus aflibercept alone and sustained efficacy and safety for six months or more following a single injection. Additional pipeline assets extend the platform toward Geographic Atrophy and other retinal indications.

Optigo's business model is licensing and partnership-driven rather than commercial. The company explicitly seeks to partner with ophthalmology pharmaceutical and biotech companies that have approved or in-development intravitreal retinal therapies, offering the anchoring platform as a durability-enhancing module. There are no commercialized products, no disclosed pricing, and no revenue; future monetization is expected through licensing royalties, development partnerships, and eventual commercialization of pipeline therapies. The leadership team includes co-founders Ali Ardakani (CEO) and Houman Hemmati MD PhD (CMO), supported by a COO, CSO, and CFO, with Dr. Andreas Wallnöfer (former Roche/Genentech R&D leader involved in Vabysmo's development and a Jeito Capital partner in the EyeBio investment) joining the Board in November 2025 as the lead program advances to IND-enabling studies.

Name

Optigo Biotherapeutics

Legal name

Optigo Biotherapeutics Inc.

Website

https://optigobio.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

Optigo Biotherapeutics is a preclinical-stage Vancouver-based biotherapeutics company developing a proprietary hyaluronic acid-anchoring platform that extends the half-life of intravitreal retinal biologics, with a lead once-yearly anti-VEGF therapy for neovascular AMD and pipeline assets for Geographic Atrophy, monetized via licensing and partnerships with ophthalmology pharma companies.

Ownership category

akta.pro rank

Product category

Ophthalmic Biotherapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Ophthalmology Specialty Pharmaceuticals (HLAIACAK)

akta.pro secondary industries

Ophthalmology Pharmaceuticals (HLAIAAAL), Ocular Drug Delivery Devices (Eye Droppers/Inserts) (HLAHAIAL), Rare Ophthalmology Disorder Therapies (HLAIAIAK), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

Keywords

• Intravitreal biologics
• Retinal disease therapeutics
• Sustained release ophthalmology
• Anti-VEGF therapy
• Vitreous anchor platform

Headquarters

HQ city

Vancouver

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Biopharmaceutical Development and Licensing: Pre-revenue preclinical stage company developing a proprietary platform for retinal disease treatments. Expected to generate revenue through licensing of technology, development partnerships, and eventual commercialization of pipeline therapies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels8 records

Core offering

Optigo Biotherapeutics is a preclinical-stage biotherapeutics company developing a proprietary hyaluronic acid (HA)-anchoring platform that enables sustained release of intravitreal biologics by anchoring therapeutic molecules to specific proteins in the vitreous gel, extending half-life and duration of action without impacting efficacy. Its lead asset is a long-acting anti-VEGF fusion therapy designed for once-yearly dosing for neovascular age-related macular degeneration (nAMD), with additional pipeline assets targeting Geographic Atrophy (GA) and other retinal indications. The company is advancing toward IND-enabling studies and first-in-human trials and intends to monetize via licensing and development partnerships with pharmaceutical companies.

Product overview

Optigo Biotherapeutics is a pre-clinical stage biotherapeutics company developing a proprietary platform-plus-pipeline architecture. The core technology is the Vitreous Anchor Platform, a modular bi-functional design that anchors intravitreal biologics to endogenous proteins in the vitreous gel (hyaluronic acid and albumin) to extend half-life and duration of action. Built on this platform, the lead asset is a long-acting anti-VEGF therapy for neovascular age-related macular degeneration (nAMD), with additional pipeline assets targeting Geographic Atrophy and other retinal diseases. The platform's modular design enables fusion of anchor molecules to various existing and future retinal biologics, creating a portfolio of extended-duration treatments designed to reduce injection frequency from monthly to twice yearly.

Differentiator

Problem solved

Functional benefit

Products and services

• Vitreous Anchor Platform A proprietary intravitreal sustained release platform that harnesses components of the vitreous gel (hyaluronic acid and albumin) to prolong the duration of existing and future intravitreal drugs used to treat retinal diseases. The platform creates bi-specific molecules that anchor biologics to the vitreous gel to extend half-life and duration of action, and is offered to ophthalmology partners for co-development.
• Long-Acting Anti-VEGF Therapy (Lead Asset) A next-generation anti-VEGF fusion therapy targeting neovascular age-related macular degeneration (nAMD), designed to be delivered once annually instead of monthly or bimonthly intravitreal injections. The therapy fuses an anti-VEGF biologic with an albumin or hyaluronan anchoring domain to significantly extend duration of action, with preclinical data demonstrating 2–3x longer half-life vs. aflibercept alone.
• Pipeline Assets for Geographic Atrophy (GA) Biologics engineered using the anchoring platform to address unmet needs across multiple retinal indications including Geographic Atrophy (GA) and other degenerative retinal diseases. The modular bi-functional design allows fusion of anchor molecules to existing and future retinal biologics, reducing injection frequency and treatment burden.

Quantifiable outcome

• 2-3x longer half-life compared to aflibercept alone in preclinical models
• +3 more outcomes

Segments4 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Dr. Andreas WallnöfercoreStrategic or Co-development Partner · 4 November 2025Renowned pharma and biotech development leader with more than 25 years of experience in pharmaceutical R&D and biotech investment joins the Board of Directors. Previously a Partner at Jeito Capital where he was an initial lead investor in EyeBio (acquired by Merck for $3B in 2024). Former General Partner at BioMedPartners involved in multiple M&A acquisitions. Served on R&D Executive Leadership Team at F. Hoffmann-La Roche AG as Global Head of Clinical Research & Exploratory Development and Head of CV&M R&D, playing key role in Vabysmo development.

Scale indicators8 records

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• Genentech / Roche: Developer and commercializer of Vabysmo (faricimab), the leading next-generation anti-VEGF therapy for retinal disease, developed in part by Optigo's new board member. The dominant large-pharma player in extended-duration retinal biologics.
• Regeneron Pharmaceuticals: Maker of Eylea (aflibercept), the blockbuster anti-VEGF therapy used in wet AMD, DME, and RVO that Optigo's lead asset is benchmarked against. Broad incumbent shaping the durability/competitive benchmark in intravitreal therapy.

Emerging players

• Annexon Biosciences: Clinical-stage biotech developing complement pathway inhibitors for retinal indications including geographic atrophy. Overlapping therapeutic area with Optigo's GA pipeline.
• Ocular Therapeutix: Commercial-stage biotherapeutics and drug delivery company with sustained-release intravitreal programs (including for retinal disease). Comparable on the sustained-release ocular delivery mechanism side of Optigo's platform.
• Outlook Therapeutics: Late clinical-stage company developing a biosimilar ranibizumab (ONS-5010/LYTENAVA) for wet AMD. Competes in the same anti-VEGF retinal therapeutics market with a different mechanism (biosimilar) targeting similar patient populations.

Direct peers

• REGENXBIO: Clinical-stage gene therapy company developing subretinal and suprachoroidal delivery for wet AMD and diabetic retinopathy. Competes on durable / one-time treatment paradigms for the same retinal indications.
• Apellis Pharmaceuticals: Commercial-stage biotech whose lead product Syfovre treats Geographic Atrophy, a key Optigo pipeline indication. Direct competitor in the GA/retinal disease space with both approved product and ongoing pipeline.
• Kodiak Sciences: Clinical-stage biotherapeutics company developing extended-duration intravitreal biologics for retinal diseases, including anti-VEGF therapies. Direct competitor pursuing longer-dosing intervals for the same wet AMD/DME indications.
• Adverum Biotechnologies: Clinical-stage gene therapy company targeting retinal diseases (wet AMD, DME) with a one-time intravitreal injection aimed at long-term anti-VEGF expression. Competes in the same extended-duration retinal biologics/durability category.
• EyeBio: Founded to develop bispecific biologics for retinal disease and was acquired by Merck for $3B in 2024. Most direct comparable: also pursued a multi-asset retinal biologics strategy targeting wet AMD/DME and was backed by Jeito Capital (same lead investor as Optigo's new board member).

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/optigobio
• LinkedInlinkedin.com/company/optigo-biotherapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Optigo Biotherapeutics